Malaysian Biotechnology Information Centre

LuminUltra | September 14, 2020

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

MedTech

Avantor | April 27, 2021

Avantor Inc., a main worldwide supplier of crucial items and administrations to clients in the existing sciences, trend-setting innovations, and applied materials businesses, today declared that it will increment worldwide limit with regards to top-notch single-use advances utilized in the creation of biologics and antibodies. In the U.S. what's more, in Europe, the Company will build its single-use producing impression by 30% and twofold its cleanroom space. The speculation w...

Acticor Biotech | October 05, 2020

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke. This Dose Escalation Phase was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy). 5 cohorts of patients presenting wit...

Cell and Gene Therapy

Astellas Pharma Inc. and Dyno Therapeutics, Inc. | December 02, 2021

Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform. Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors...